Literature DB >> 2302706

c-myc down regulation and precommitment in HL-60 cells due to bromodeoxyuridine.

A Yen1, M E Forbes.   

Abstract

HL-60 human nonlymphocytic leukemia cells undergo terminal differentiation along either the myeloid or monocytic pathway in a process previously shown to involve two sequential steps, early events leading to a precommitment state and late events leading to onset of terminal differentiation. The present report shows that bromodeoxyuridine induces the early events leading to precommitment. In this course bromodeoxyuridine causes the rapid down regulation of the c-myc protooncogene. The course is similar to other common inducers of HL-60 differentiation including retinoic acid, dimethyl sulfoxide, 1,25-dihydroxyvitamin D3, and sodium butyrate. HL-60 cells which were initially exponentially proliferating were exposed to 10 microM bromodeoxyuridine for 24 h, a period corresponding to one division cycle in these cells. When the cells were subsequently exposed to either retinoic acid or 1,25-dihydroxyvitamin D3, onset of G1/0 specific growth arrest and display of the differentiated phenotype occurred within 24 h. This is in contrast to the 48-h exposure needed for onset of terminal differentiation if either inducer is used singly during continuous exposure, as has been reported previously. Thus bromodeoxyuridine consummated the early events, including the rapid down regulation of c-myc message levels, which occur during the first division cycle of the induced cellular metabolic cascade leading to onset of terminal differentiation. The ability of bromodeoxyuridine to drive events in the metabolic cascade leading to onset of terminal differentiation was specific for early events, inasmuch as it was relatively ineffective at driving late events. Down regulation of c-myc was not in itself sufficient to result in subsequent terminal differentiation, since pulse exposure to bromodeoxyuridine followed by culture in inducer free medium resulted in little G1/0 specific growth arrest or phenotypic differentiation. Continuous exposure to bromodeoxyuridine, in contrast, resulted in significant G1/0 specific growth arrest but little phenotypic differentiation, indicating that the regulation of cell cycle transit and differentiation are separable.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2302706

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells.

Authors:  S H Cheshier; S J Morrison; X Liao; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Bromodeoxyuridine increases keratin 19 protein expression at a posttranscriptional level in two human lung tumor cell lines.

Authors:  P Meleady; M Clynes
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-09       Impact factor: 2.416

3.  1,25-Dihydroxy vitamin D2 induces leukemia cell differentiation.

Authors:  A Yen; J Blue; M Forbes
Journal:  In Vitro Cell Dev Biol       Date:  1991-07

4.  Paxillin increases as retinoic acid or vitamin D3 induce HL-60 cell differentiation.

Authors:  J D Platko; A Yen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-02       Impact factor: 2.416

5.  Retinoic acid increases amount of phosphorylated RAF; ectopic expression of cFMS reveals that retinoic acid-induced differentiation is more strongly dependent on ERK2 signaling than induced GO arrest is.

Authors:  A Yen; S Varvayanis
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-04       Impact factor: 2.416

6.  Polyomavirus small t antigen prevents retinoic acid-induced retinoblastoma protein hypophosphorylation and redirects retinoic acid-induced G0 arrest and differentiation to apoptosis.

Authors:  A Yen; L Placanica; S Bloom; S Varvayanis
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells.

Authors:  Ryan Tasseff; Satyaprakash Nayak; Sang Ok Song; Andrew Yen; Jeffrey D Varner
Journal:  Integr Biol (Camb)       Date:  2011-03-24       Impact factor: 2.192

8.  RB tumor suppressor gene expression responds to DNA synthesis inhibitors.

Authors:  A Yen; S Varvayanis
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

9.  Retinoic acid therapy resistance progresses from unilineage to bilineage in HL-60 leukemic blasts.

Authors:  Holly A Jensen; Rodica P Bunaciu; Christopher N Ibabao; Rebecca Myers; Jeffrey D Varner; Andrew Yen
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

10.  Estimating dormant and active hematopoietic stem cell kinetics through extensive modeling of bromodeoxyuridine label-retaining cell dynamics.

Authors:  Richard C van der Wath; Anne Wilson; Elisa Laurenti; Andreas Trumpp; Pietro Liò
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.